April 13, 2010

Data from AVEO Pharmaceuticals’ Translational Research Platform and Novel Antibody Pipeline to be Presented at AACR 101st Annual Meeting 2010

Download PDF

CAMBRIDGE, Mass., Apr 13, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that preclinical data from its translational research platform and antibody pipeline will be presented during six poster sessions at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 being held April 17-21, 2010, in Washington, D.C.

“We look forward to sharing with our peers in the oncology community preclinical data from AVEO’s translational research platform and antibody discovery programs,” stated Murray O. Robinson, Ph.D., senior vice president, translational medicine, AVEO Pharmaceuticals. “The data being presented at AACR show the maturation of our Human Response Platform(TM) which continues to play an important role in our clinical development and antibody discovery programs.”

The schedule for AVEO poster presentations is as follows:
Date & Time:Sunday, April 18, 2010 at 2:00 p.m. EDT
Session Title:New Molecular Targets 1: Models, Imaging and Molecular Classification
Location:Exhibit Hall A-C, Poster Section 24, Poster Number 13
Presenter:Lorena Lerner
Date & Time:Monday, April 19, 2010 at 9:00 a.m. EDT
Session Title:Novel/New Antiangiogenic Therapeutic Approaches
Location:Exhibit Hall A-C, Poster Section 15, Poster Number 18
Presenter:Yinghui Zhou
Date & Time:Monday, April 19, 2010 at 2:00 p.m. EDT
Session Title:Cancer Genomics and Bioinformatics 2
Location:Exhibit Hall A-C, Poster Section 1, Poster Number 23
Presenter:Bin Feng
Date & Time:Tuesday, April 20, 2010 at 9:00 a.m. EDT
Session Title:Animal Models of Breast and Ovarian Cancer
Location:Exhibit Hall A-C, Poster Section 13, Poster Number 14
Presenter:Min Wu
Date & Time:Wednesday, April 21, 2010 at 8:00 a.m. EDT
Session Title:Cancer Stem Cell Biology 3
Location:Exhibit Hall A-C, Poster Section 12, Poster Number 29
Presenter:Ronan O’Hagan
The schedule for the AVEO and OSI Pharmaceuticals collaborative poster presentation is as follows:
Date & Time:Monday, April 19, 2010 at 9:00 a.m. EDT
Session Title:Novel Mechanisms of Drug Action and Signaling Pathways
Location:Exhibit Hall A-C, Poster Section 26, Poster Number 24
Presenter:Elizabeth Buck

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) blends a proprietary cancer biology platform with drug development and commercial expertise to discover and develop targeted cancer therapeutics. The company’s lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with potential for a best-in-class profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEO’s proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development that both increases the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGFErbB3RON, Notch and FGFR. For more information, please visit the company’s website at www.aveopharma.com.

Any statements in this press release about our future expectations, plans and prospects, including statements about the company’s cancer biology platform increasing the probability of clinical success and providing a discovery engine for high-value targets, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: our ability to successfully research, develop and obtain and maintain regulatory approvals for tivozanib and our other product candidates; our inability to obtain and maintain adequate protection for intellectual property rights relating to our product candidates and technologies; unplanned operating expenses and our ability to raise substantial additional funds to achieve our goals; general economic and industry conditions; and other factors discussed in the “Risk Factors” section of the final prospectus relating to our initial public offering filed with the Securities and Exchange Commission, and in other filings that we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

SOURCE: AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals, Inc.
David Johnston,Chief Financial Officer, 617-299-5810
Pure Communications
Caton Lovett, 910-232-7166